Trogenix doses first patient in Phase I/II clinical trial of TGX-007 gene therapy for glioblastoma
UK and US trial sites open; first patient dosed with TGX-007, Trogenix’s proprietary dual-payload AAV gene therapy TGX-007 leverages Trogenix’s precision synthetic super-enhancer platform that selectively activates therapeutic immune payloads within tumour …